FDA Hits Hong Kong-Based Drugmaker Over cGMP Concerns Surrounding Procedures

International Pharmaceutical Regulatory Monitor
A A
The FDA issued a warning letter Jan. 15 to a Hong Kong drugmaker for allegedly significant cGMP violations that led to adulterated products and data issues.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00